Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor

Abstract

The pathogenesis of thyroid eye disease (TED) has been suggested as due to signal enhancement in orbital fibroblasts as a result of autoantibody-induced, synergistic interaction between the TSH receptor (TSHR) and the IGF-1 receptor (IGF-1R). This interaction has been explained by a "receptor cross-talk," mediated via β-arrestin binding. Here we have examined if this interaction can be mediated via direct receptor contact using modeling and experimental approaches. First, we docked a model of the leucine-rich domain of the TSHR ectodomain (ECD) to an available cryo-electron microscopy-based structure of the active-state IGF-1R dimer and demonstrated the stability of the complex using molecular dynamics simulations. We then extended the complex with the full-length TSHR and the transmembrane helices of the IGF1R and a 3000 ns simulation also showed stability of this complex. We then performed coimmunoprecipitation studies with anti-TSHR and anti-IGF-1R antibodies using cells expressing the IGF-1R and the full-length TSHR and also cells that expressed the IGF-1R and only the TSHR-ECD and, therefore, unable to bind β-arrestin. These studies showed a 360 kD complex protein in the immunoprecipitation, which was present in both the full-length TSHR and the TSHR-ECD-only expressing cells, evidencing a direct interaction of receptors via their ectodomains in the absence of arrestin. Colocalized staining of TSHR and IGF-1R in the TSHR-ECD cells further supported this direct interaction. These data showed that the TSHR and IGF-1R can interact directly and in the absence of β-arrestin binding. Understanding these interactions is important in the pathogenesis of TED and its therapeutic intervention.

Keywords: insulin-like growth factor 1 receptor; molecular dynamics; thyroid eye disease; thyroid stimulating hormone receptor; transmembrane domain.